PDCD1 and mature T-cell and NK-cell non-Hodgkin lymphoma: This study represented the largest prospective clinical trial evaluating the efficacy and safety of PD-1 inhibitors in patients with PTCL, with geptanolimab showing good promise and a manageable safety profile (Shi et al., 2021).